Peg L-ASAPARGIN 3750 I.U./5ml Vials

Peg L-ASAPARGIN

Active Ingredient:
Pegaspargase Injection
Form:
Vials
Brand:
Peg L-ASAPARGIN
Origin:
India

Buy Peg L-ASAPARGIN Pegaspargase Injection

Peg L-ASAPARGIN (Pegaspargase Injection) is an enzyme therapy used in chemotherapy regimens. Supplied as 3750 I.U./5ml vials, it helps manage certain cancers by reducing asparagine levels. This product is manufactured in India and intended for professional medical use.

Strength

3750 I.U./5ml

Manufacturer / TM Owner

Samarth Life Sciences

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Uses / Indications

  • Peg L-ASAPARGIN is primarily used as part of combination chemotherapy for the treatment of acute lymphoblastic leukemia (ALL). It works by depleting asparagine, an amino acid that cancer cells need to grow. This medication is often prescribed when other forms of asparaginase are not suitable. It may also be used off-label for other conditions as determined by a healthcare provider.

Side Effects

  • Peg L-ASAPARGIN helps slow or stop the growth of cancer cells by reducing asparagine levels in the body. Patients may experience changes in energy levels or appetite during treatment. Regular monitoring by a healthcare professional is recommended to assess response and manage any effects.

Precautions & Warnings

  • This medication should only be handled and administered by trained healthcare professionals. Patients with a history of pancreatitis, blood clotting disorders, or severe liver problems should use this medication with caution. Pregnant or breastfeeding individuals should consult their doctor before use. Proper storage and disposal of vials are essential.

Avoid Interactions

  • Peg L-ASAPARGIN may interact with other medications, including blood thinners, immunosuppressants, and certain vaccines. Combining it with live vaccines is generally not recommended. Patients should inform their healthcare provider about all medications and supplements they are taking. Alcohol use should be avoided during treatment.

References

Frequently Asked Questions

Peg L-ASAPARGIN is used in chemotherapy to treat certain cancers, primarily acute lymphoblastic leukemia (ALL).

It is given as an injection by a healthcare professional, typically as part of a larger treatment plan.

Side effects may include nausea, fatigue, or changes in blood test results. Always consult a doctor for personalized advice.

Pregnant individuals should discuss risks and benefits with their healthcare provider before using this medication.

Peg L-ASAPARGIN is manufactured by Samarth Life Sciences in India.

Published by GNH India Pharmaceuticals Limited

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pegaspargase Injection

Pegaspire

Pegaspire

3750 I.U.
Pegaspire

Pegaspire

3750 I.U./5ml Vials